Back to Journals » Oncolytic Virotherapy » Volume 7

The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses

Authors Pelin A, Wang J, Bell J, Le Boeuf F

Received 14 December 2017

Accepted for publication 31 January 2018

Published 28 March 2018 Volume 2018:7 Pages 25—35

DOI https://doi.org/10.2147/OV.S137159

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Athanasios Kyritsis


Adrian Pelin,1,2 Jiahu Wang,2,3 John Bell,1,2 Fabrice Le Boeuf2

1Department of Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Center for Cancer Therapeutics, Ottawa, ON, Canada; 3Genvira Biosciences, Ottawa Hospital Research Institute, Ottawa, ON, Canada

Abstract: Oncolytic viruses (OVs) are an emergent and unique therapy for cancer patients. Similar to chemo- and radiation therapy, OV can lyse (kill) cancer cell directly. In general, the advantages of OVs over other treatments are primarily: a higher safety profile (as shown by less adverse effects), ability to replicate, transgene(s) delivery, and stimulation of a host’s immune system against cancer. The latter has prompted successful use of OVs with other immunotherapeutic strategies in a synergistic manner. In spite of extended testing in pre-clinical and clinical setting, using biologically derived therapeutics like virus always raises potential concerns about safety (replication at non-intended locations) and bio-availability of the product. Recent advent in in vivo imaging techniques dramatically improves the convenience of use, quality of pictures, and amount of information acquired. Easy assessing of safety/localization of the biotherapeutics like OVs became a new potential weapon in the physician’s arsenal to improve treatment outcome. Given that OVs are typically replicating, in vivo imaging can also track virus replication and persistence as well as precisely mapping tumor tissues presence. This review discusses the importance of imaging in vivo in evaluating OV efficacy, as well as currently available tools and techniques.

Keywords: oncolytic virus, mouse imaging, NIS virus, viral efficacy, clinical trial
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]